MED-X, Inc. has taken a significant step toward becoming a publicly traded company by filing an amended registration statement for a direct listing on the Nasdaq Global Market. This move is crucial for the agricultural chemicals company as it seeks to enhance its visibility and access to capital.

The filing, submitted on October 29, 2026, is an amendment to the company's previous registration statement. The company aims to list its common stock under the symbol "MXRX." Unlike a traditional initial public offering (IPO), this listing allows existing shareholders to sell their shares directly in the market without the backing of an underwriter.

Background

MED-X, Inc., classified under the SIC code 2870 for Agricultural Chemicals, is incorporated in Nevada. The company has been active in the agricultural sector since its inception on February 14, 2014. It has raised approximately $38.08 million in net proceeds from stock sales up to October 14, 2026, at an average price of $2.89 per share. The company has not yet established a public trading history but has engaged Maxim Group LLC as its financial advisor for the listing process.

What the Filing Says

The recent filing states, "This prospectus relates to the registration of the resale of up to 16,248,842 post-split shares of our common stock by our stockholders identified in this prospectus." This indicates that the company is preparing for a significant number of shares to be available for trading once the listing is effective.

Impact

The filing may affect existing stockholders and potential investors looking to engage with MED-X, Inc. The direct listing approach is seen as a way to provide liquidity for current shareholders while attracting new investors. The agricultural chemicals industry, where MED-X operates, is witnessing a trend towards innovative funding methods, reflecting a shift in how companies engage with the market.

What's Next

The company expects its common stock to begin trading on Nasdaq on or about a date yet to be determined. However, the filing also notes that if the Nasdaq application is not approved, the direct listing will not proceed.